Skip to main content
. 2021 Feb 15;11(2):e041543. doi: 10.1136/bmjopen-2020-041543

Table 3.

Effect of NSAID or antibiotic use on the risk of AKI among current PPI users

Current use Cases (n=317) Controls (n=3150) OR (95% CI)* OR (95% CI), adjusted†
PPIs with NSAIDs 51 95 3.92 (2.40 to 6.52) 3.12 (1.84 to 5.37)
PPIs without NSAIDs 97 560 Reference Reference
PPIs with penicillins 15 73 0.75 (0.39 to 1.39) 0.83 (0.42 to 1.59)
PPIs without penicillins 133 582 Reference Reference
PPIs with macrolides 12 83 0.46 (0.21 to 0.89) 0.47 (0.21 to 0.96)
PPIs without macrolides 136 572 Reference Reference
PPIs with cephalosporins 25 55 2.57 (1.43 to 4.62) 1.88 (1.02 to 3.47)
PPIs without cephalosporins 123 600 Reference Reference
PPIs with fluoroquinolones 17 31 3.08 (1.50 to 6.38) 2.35 (1.12 to 4.95)
PPIs without fluoroquinolones 131 624 Reference Reference

*ORs of AKI for current drug combinations compared with PPIs alone were estimated using the conditional logistic regression model.

†Adjusted ORs were estimated by entering the potential confounders into the model.

AKI, acute kidney injury; NSAIDs, non-steroidal anti-inflammatory drugs; PPIs, proton pump inhibitors.